Royal Bank Of Canada Evelo Biosciences, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.44 - $48.2 $187 - $6,266	-130 Reduced 90.28%	14 $0
Q3 2022 Nov 14, 2022	BUY	$1.86 - $41.8 $267 - $6,019	144 New	144 $0
Q2 2022 Aug 15, 2022	SELL	$1.46 - $3.55 $3,315 - $8,062	-2,271 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.66 - $6.63 $11,725 - $29,225	-4,408 Reduced 66.0%	2,271 $7,000
Q4 2021 Feb 14, 2022	BUY	$6.07 - $12.0 $20,534 - $40,596	3,383 Added 102.64%	6,679 $40,000
Q3 2021 Nov 15, 2021	BUY	$6.79 - $13.9 $8,263 - $16,916	1,217 Added 58.54%	3,296 $23,000
Q2 2021 Aug 16, 2021	BUY	$9.43 - $16.6 $19,604 - $34,511	2,079 New	2,079 $29,000

Ticker EVLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,994,000
Description
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hy...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.